Drug Profile
SC 006
Alternative Names: SC-006Latest Information Update: 16 Jul 2020
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
- Mechanism of Action Antibody-dependent cell cytotoxicity; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 22 Jun 2020 Adverse events and efficacy data from phase I trial in Colorectal cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 28 Apr 2020 No recent reports of development identified for phase-I development in Colorectal-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV)